Our programs are directed at treating metabolic diseases to minimize their long-term complications through end-organ protection.

PROGRAM	PRECLINICAL PHASE 1 PHASE 2 PHASE 3	PARTNER	TERRITORY
TTP399 (GKA)	Type 1 Diabetes
Azeliragon (RAGE)	Dementia with Diabetes
TTP273 (Oral GLP-1R)	Cystic Fibrosis Related Diabetes (CFRD)
Nrf2/Bach1	Undisclosed
Partnered Programs
TTP273 (Oral GLP-1R)	Type 2 Diabetes		Asia (*ROW retained)
HPP593 (PPAR-δ)	Fatty Acid Oxidation Disorders		Worldwide
HPP737 (PDE4i)	COPD		Asia (*ROW retained)

Our programs are directed at treating metabolic diseases to minimize their long-term complications through end-organ protection.